Corporate ActionMay 8, 2026, 08:37 AM
Alamar Biosciences Completes IPO, Q1 Revenue +98.8% to $26.0M
AI Summary
Alamar Biosciences, Inc. completed its Initial Public Offering (IPO) on April 20, 2026, generating $197.8 million in net proceeds, following a one-for-2.418 reverse stock split on April 10, 2026. For the first quarter of 2026, the company reported a significant 98.8% increase in total revenue to $26.0 million, driven by strong product sales. However, the net loss for the quarter also widened to $21.3 million, reflecting increased operating expenses and a loss on remeasurement of convertible notes.
Key Highlights
- Completed IPO on April 20, 2026, raising $219.9M gross and $197.8M net proceeds.
- Effected a one-for-2.418 reverse stock split on April 10, 2026.
- Q1 2026 total revenue increased 98.8% to $26.0 million from $13.1 million in Q1 2025.
- Q1 2026 net loss increased to $21.3 million from $7.7 million in Q1 2025.
- Product revenue for Q1 2026 grew 132.7% to $21.3 million from $9.2 million.
- Cash and cash equivalents were $64.6 million as of March 31, 2026.
- Issued $56.5 million in convertible notes during the first quarter of 2026.
Price Impact
More from ALMR